Press Releases

CureDuchenne, an Official Charity of the Run Disney Tinker Bell Half Marathon, Encourages Runners to Join Team to Raise Funds to Find a Cure for Duchenne

CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, is proud to be an official charity of the Tinker Bell Half Marathon. The Tinker Bell Half Marathon weekend is January 17-19, 2014. Runners are encouraged to join the CureDuchenne team and help raise funds to find a cure for Duchenne, a progressive muscle-wasting disease. Spots for the Tinker Bell Half Marathon are still available through CureDuchenne.

CureDuchenne Comments on U.S. Food and Drug Administration Breakthrough Therapy designation for GlaxoSmithKlineÌ¢‰â‰ã¢s/Prosensa Therapeutics’ drisapersen for Treatment of Patients with Duchenne Muscular Dystrophy

CureDuchenne is pleased that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to drisapersen, an exon-51 skipping compound for the potential treatment of patients with Duchenne Muscular Dystrophy. Drisapersen is being developed by GlaxoSmithKline plc (GSK) and licensed from Prosensa Therapeutics.

Celebrities to Join 6th Annual Dealing for Duchenne Gala on May 11

CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announces the 6th Annual Dealing for Duchenne gala will be held on Saturday, May 11 at 6:00 p.m. under the stars at the legendary Sony Pictures Studios in Culver City, Calif. This star-studded event will benefit the Center for Duchenne Muscular Dystrophy at UCLA. Actor Joel Murray (The Artist, God Bless America, Mad Men, Two and a Half Men) will host the Dealing for Duchenne charity poker tournament to raise funds to support transformative research and provide quality care for children living with Duchenne, a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Boys are usually diagnosed by 5, in a wheelchair by 12 and most donÌ¢‰â‰ã¢t survive their mid-20s.

Jim Ruetz to Embark on the Cajun-Parrot Run, a 4,000-Mile Motorcycle Trip to Raise Funds to Find a Cure for Duchenne Muscular Dystrophy

Jim Ruetz of Oak Creek, Wisconsin, will embark on a 4,000-mile, 12-day motorcycle trip across 12 states in the Cajun-Parrot Run to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Ruetz starts his journey on June 5 from Oak Creek. In route, heÌ¢‰â‰ã¢ll stop in New Orleans, his furthest waypoint is Key West, Fla., Ruetz will make his way back to Wisconsin on or near June 18.

CureDuchenne Partners with French Researchers to Expand eDystrophin Database

CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, has partnered with Dr. Elisabeth Le Rumeur and Pr Jean-FranÌÄå¤ois Hubert, researchers from the Institute of Genetics and Development of Rennes at the University of Rennes 1 in France, to expand the eDystrophin database. The aim of the partnership is to advance our knowledge about dystrophin mutations found in Becker muscular dystrophy (BMD) patients.

Hockey Players Raise Funds to Find a Cure for Duchenne Muscular Dystrophy During Weekend Ice Duchenne Event to Benefit CureDuchenne

Western Michigan University is hosting a weekend long Ì¢‰âÒIce DuchenneÌ¢‰âÂÌ_ fundraiser on February 22-23 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. The Western Michigan University Bronco hockey team, a member of the Central Collegiate Hockey Association (CCHA), will sell raffle tickets to raise money and help find a cure for Duchenne. To promote the cause, Scott Niedermayer, one of the most decorated hockey players of all-time, is also featured in a public service announcement that is planned to debut with the event.

CureDuchenne Hosts Accelerateed Access Webinar with the FDA

CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host a webinar on accelerated access for drug approvals with the Food and Drug Administration (FDA) on February 20, 2013 at 4 p.m. EST for Duchenne parents and advocates. Dr. Robert Temple, Deputy Center Director for Clinical Science, Center for Drug Evaluation and Research, FDA, will present and discuss expedited pathway programs, legislative initiatives and expanded access to investigational drugs. As the most common and lethal form of muscular dystrophy, Duchenne impacts 1 in 3,500 boys. There is currently no cure for Duchenne.